<DOC>
	<DOCNO>NCT00387608</DOCNO>
	<brief_summary>RATIONALE : ABT-888 may stop growth cancer cell block enzymes need cell growth . Collecting store sample blood patient cancer study laboratory may help doctor learn way patient 's body handle drug . PURPOSE : This early phase I trial study side effect best dose ABT-888 patient refractory solid tumor hematologic cancer .</brief_summary>
	<brief_title>ABT-888 Patients With Refractory Solid Tumors Hematologic Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine dose-range ABT-888 inhibits poly ( ADP-ribose ) polymerase ( PARP ) tumor sample peripheral blood mononuclear cell ( PBMCs ) patient refractory solid tumor lymphoid malignancy . - Determine pharmacokinetics ABT-888 . - Determine time course PARP inhibition PBMCs ABT-888 . Secondary - Determine safety administer 1 dose ABT-888 patient . OUTLINE : This dose-finding study . Patients receive oral ABT-888 day 1 . Cohorts 3 patient receive escalate dos ABT-888 significant tumor poly ( ADP-ribose ) polymerase ( PARP ) inhibition observe 3 3 patient 2 dose level . Significant PARP inhibition define ≥ 0.69 reduction log scale poly ( ADP-ribose ) level baseline 3-6 hour ABT-888 administration ( 90 % confidence due chance variation ) . Patients undergo peripheral blood collection baseline periodically ABT-888 administration PARP inhibition , pharmacokinetic , pharmacodynamic study . Once significant PARP inhibition observe 1 3 patient , subsequently enrol patient also undergo tumor biopsy* baseline 3-6 hour 21-27 hour ABT-888 administration determine PARP inhibition tumor tissue . NOTE : *Patients chronic lymphocytic leukemia undergo peripheral blood collection instead biopsy . After completion ABT-888 administration , patient follow 7 day . PROJECTED ACCRUAL : A total 23 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Veliparib</mesh_term>
	<mesh_term>Poly ( ADP-ribose ) Polymerase Inhibitors</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm malignancy , meet 1 follow criterion : Solid tumor refractory ≥ 1 line standard treatment OR standard therapy available Must ≥ 1 lesion amenable percutaneous biopsy ( solid tumor patient enrol initial phase study ) Chronic lymphocytic leukemia ( CLL ) follicular lymphoma current indication standard therapy OR disease fail ≥ 1 line standard therapy No diseaseassociated symptom require immediate therapy intervention Must willing undergo tumor biopsies* initial phase study NOTE : *Patients CLL undergo peripheral blood collection instead biopsy No primary brain tumor , brain metastasis , leptomeningeal disease PATIENT CHARACTERISTICS : ECOG performance status ( PS ) 02 Karnofsky PS 60100 % Life expectancy ≥ 3 month Absolute neutrophil count ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Hemoglobin ≥ 9 g/dL Bilirubin &lt; 1.5 time upper limit normal ( ULN ) AST ALT ≤ 2.5 time ULN Creatinine &lt; 1.5 time ULN OR creatinine clearance ≥ 60 mL/min INR ≤ 1.4 PTT ≤ 36 second Calcium ( correct ) normal Magnesium &lt; 1.5 time ULN Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 30 day study completion No history seizures No evidence bleed diathesis No uncontrolled intercurrent illness include , limited , follow : Ongoing active infection Symptomatic congestive heart failure Unstable angina pectoris Cardiac arrhythmias No psychiatric illness social situation would limit study compliance PRIOR CONCURRENT THERAPY : At least 2 week since prior radiation therapy surgery recover At least 2 week since prior therapy recover No concurrent antiretroviral therapy HIVpositive patient No concurrent lung , liver , mediastinal lymph node biopsies No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
</DOC>